Related Experiment Video

Updated: Jun 17, 2025

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
02:21

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease

Published on: March 15, 2024

604

The Princeton IV Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease

Tobias S Köhler1, Robert A Kloner2, Raymond C Rosen3

  • 1Department of Urology, Mayo Clinic, Rochester, MN.

Mayo Clinic Proceedings
|August 8, 2024
PubMed

Insights

Men with erectile dysfunction (ED) should be treated as high-risk for cardiac events. New guidelines update ED diagnosis and treatment, incorporating coronary artery calcium scoring and exploring phosphodiesterase type 5 inhibitors.

Area of Science:

  • Cardiovascular Medicine
  • Sexual Health
  • Men's Health

Background:

  • The Princeton Consensus Conference series focuses on optimizing sexual function and cardiovascular health.
  • Previous panels (I-III) addressed erectile dysfunction (ED) in men with cardiovascular disease (CVD).
  • Princeton IV convenes 13 years after Princeton III, building upon established knowledge.

Purpose of the Study:

  • To update clinical management strategies for men with ED and CVD.
  • To integrate new evidence into diagnostic and treatment algorithms.
  • To explore the role of phosphodiesterase type 5 (PDE5) inhibitors in this patient population.

Main Methods:

  • Multispecialty expert panel review and consensus development.
  • Integration of mounting evidence regarding ED as a marker for CVD risk.
  • Updated recommendations for diagnostic tools, including coronary artery calcium scoring.
  • Review of current therapeutic options, including PDE5 inhibitors.

Main Results:

  • Strong evidence supports treating men with ED as being at risk for cardiac events until proven otherwise.
  • Updated algorithms for ED diagnosis and treatment are provided.
  • Coronary artery calcium scoring is recommended for advanced cardiovascular risk stratification.
  • Optimization of oral PDE5 inhibitors is discussed, including potential cardioprotective effects.

Conclusions:

  • ED is a significant indicator of underlying cardiovascular risk.
  • A proactive approach to cardiovascular risk assessment and management is crucial in men with ED.
  • PDE5 inhibitors may offer benefits beyond erectile function in men with CVD.

More Related Videos

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents08:03

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents

Published on: June 6, 2018

14.2K
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.3K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
140
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
370
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.1K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
164
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
557
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406